☰
×
News
Top 20
Insights
Insights+
ThoughtSpot
Interviews
Viewpoints
Exclusive
Spotlight
Events
Magazine
Bespoke
Newswire
x
Search
Search here
Search here
Subscribe Now
ultomiris
Alexion to Discontinue its P-III CHAMPION-ALS Trial of Ultomiris (ravulizumab) for Amyotrophic Lateral Sclerosis
August 23, 2021
Apellis' Empaveli (pegcetacoplan) Receives the US FDA's Approval for Paroxysmal Nocturnal Hemoglobinuria
May 17, 2021
Load more...
Back to Home
Modal title
×
Modal body text goes here.
